Case study:
From FDA Approval to EU Marketing Authorisation: Transforming Module 3 for EMA Submission
Background:
A small-to-mid-sized biotech company successfully obtained FDA approval for its New Drug Application (NDA) and sought to leverage the same Chemistry, Manufacturing and Controls (CMC) dossier to support a subsequent EU Marketing Authorisation Application (MAA)
Challenge
Following US approval, the client’s initial strategy was to submit Module 3 to the European Medicines Agency (EMA) with only minimal modifications. The dossier had been compiled by multiple subject matter experts (SMEs) and on initial review was:
- Highly US-centric in writing style and scientific justification
- Reliant on FDA guidance references, US regulatory interactions and DMF references
- Lacking alignment with EU expectations, including Ph. Eur. standards
The client engaged Boyd to conduct a comprehensive gap analysis to assess the suitability of the existing Module 3 for EU submission.
Solution
Boyds performed a detailed review of Module 3 to identify:
- Critical data gaps requiring new studies or analyses
- Sections where scientific justifications required repositioning or rewording to align with EU regulatory expectations
- Inconsistencies across the control strategy, particularly where different sections had been authored independently
Key findings included:
- Gaps in stability data package when assessed against EU specific requirements
- Dissolution method justification based solely on FDA guidance, with limited product-specific rationale
- Nitrosamine risk assessment identified potential concerns and lacked sufficient supporting data to fully meet EU expectations
Based on the findings, Boyds collaborated with the client to define a targeted action plan, including:
- Designing and initiating additional studies where gaps were identified
- Rewriting sections to:
- Align with EU regulatory language and expectations
- Include clear data-led narratives
- Ensure compliance with Ph. Eur. requirements
- Improve consistency across Module 3
- Add detail to replace DMF references
Where data generation timelines were constrained, Boyds supported:
- Strategic interactions with EU regulators
- Agreement of post-approval commitments where appropriate
Impact and Outcomes
- The revised Module 3 was successfully submitted as part of the EU MAA
- The application was ultimately approved, with some agreed post-approval commitments
- Key learning:
A Module 3 supporting FDA approval is not automatically suitable for EU submission without significant adaptation